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Genetic diseases have always been present in the animal population but their significance has 
increased in recent decades. The wealth of knowledge on genomic information, systems biology and 
mechanisms of diseases provide great opportunities to elucidate the genetic bases of diseases. The 
use of recombinant DNA techniques in conjunction with conventional genetic methods have led to a 
rapid increase in knowledge of the genetic map. Many animal genes have been mapped to 
chromosomes. A detailed genetic map has become of great value in the diagnosis of genetic diseases 
and in the development of potential cures through gene transfer therapy. In view of the emerging animal 
diseases like avian influenza, swine influenza among others with serious health implications for 
humans, this review aims at highlighting the association between diseases and genes in animals. The 
information derived could assist in the prevention and management of emerging animal diseases and in 
future drug discovery processes.  
 





The development in gene technology is based on the 
discoveries in molecular biology by Watson and Crick 
(1953), with the discovery of the double helical structure 
of DNA and the breaking of the genetic code. The model 
for the DNA molecule described by Watson and Crick 
explains how DNA molecules are duplicated, that is, the 
process of DNA replication. Deoxyribonucleic acid (DNA) 
is the most important molecule in living cells. It carries 
within its structure the hereditary information which deter-
mines the structures of proteins to be synthesized 
(Bewaji, 2003). The instructions for cell division, growth 
and differentiation are also encoded in DNA. DNA is 
usually located in the cell nucleus and mitochondria on 
coiled ladder-like structures called chromosomes. Cells 
which contain a nucleus are referred to as eukaryotic 
cells, while those without clearly defined nucleus, such as 
bacteria and blue-green algae, are known as prokaryotic 
cells. The number of chromosomes per cell varies with 
species. Bacterial cells usually contain between one and 
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molecules called plasmids. These can be replicated 
along with the chromosomes. Some of them, called epi-
somes, have the ability to move on and off the main chro-
mosome.  
Methods have been devised for isolating plasmids from 
bacteria, incorporating other DNA molecules into them 
and then re-introducing the new (hybrid) plasmid into the 
bacteria. The newly incorporated DNA will then replicate 
along with the rest of the plasmid. 
It is now becoming increasingly clear that genes and 
their products interact in complex biological networks and 
distortions of these networks contribute to disease states 
(Sakharkar and Sakharkar, 2008). The network of genes 
and diseases demonstrates how the aberrant network 
gene/protein nodes contribute to disease(s) and defines 
the multiple protein nodes that can be targeted to restore 
the network. This provides an example of integrating 
molecular/biochemical and physiological information 
needed to capture the diverse characteristics of complex 
disorders.  
Veterinary genetics encompasses those aspects of 
genetics that are relevant to animal diseases and to 
animal production (Nicholas, 1993). The importance of 





recent decades. This is because vaccination program-
mes, antibiotics and improved sanitations have reduced 
the incidence or prevalence of infectious diseases of 
animals. This results in a greater population of animals 
now dying from a disease that has genetic component, 
especially the late onset diseases. Veterinary and genetic 
research has been successfully used in diagnosis and 
control of many infectious diseases of animals. There are 
many reasons why identifying the gene responsible for a 
disease is important. These include: 
 
1. All diseases have genetic bases (Murray et al., 2000). 
2. Gene identification may provide an indication of the 
biochemical basis to the disease, thus enabling therapies 
to be designed (Brown, 1998). 
3. Identification of the defective gene is a prerequisite for 
gene therapy. 
4. Identification of the mutation present in a defective 
gene can be used to devise a screening programme so 
that the mutant gene can be identified in individuals who 
are carriers or who have not yet developed the disease 
(Brown, 1998). 
 
Early identification of individual animals that have not yet 
developed the disease allows appropriate precautions to 
be taken to reduce the risk of the disease becoming 
expressed. During the last few years, a number of genes 
responsible for inherited diseases have been identified. 
Once a gene associated with a single gene disorder has 
been isolated and cloned, it is usually easy to develop a 
gene-based diagnostic test. This can be used to confirm 
the diagnosis of an existing condition, as a prognostic 
indicator that an individual animal will eventually develop 
a disease, or may be at increased risk of developing 
disease conditions or to reveal information on a healthy 
individual animal’s carrier status. The growing number of 
pathogen sequencing programmes in which scientists are 
deciphering genomes of microbes of medical and 
veterinary importance is also beginning to yield new, less 
controversial diagnostic tools.  
 
 
GENETICS AND ANIMAL DISEASES        
  
The application of genetics to the diagnosis of animal 
diseases has been mentioned by Hauge, (1989). The 
availability of DNA clones or the knowledge of primer se-
quences from humans and experimental animals has 
enhanced this development. Examples of the use of 
genetics for the diagnosis of disease mutations include: 
 
(i) Deficiency of uridine monophosphate synthase 
(DUMPS) in bovine is an autosomal recessive disorder in 
Holstein and Red Holstein cattle, that results in early 
embryonic death of homozygous offspring (Hauge, 1989). 
Heterozygotes are phenotypically normal, but show about 
one-half the normal enzyme level and  elevated  levels  of  




orotic acid. Heterozygotes may have a higher genetic 
advantage in milk and protein production. With accurate 
DNA-based genotyping, it would be possible to preserve 
the mutation in the population while avoiding matings 
between carriers. Schober et al. (1992) have also iso-
lated and sequenced wild type bovine UMPS cDNA using 
a human UMPS-specific cDNA to screen the library. 
Genetic studies were carried out which showed that 
complete concurrence between low levels of UMPS, pre-
sence of the point mutation was found in a large Holstein 
pedigree, and this confirmed that this mutation was the 
basic defect in DUMPS cattle.  
(ii) Cittrullinemia in cattle: Cittrullinemia is widespread in 
Australian Friesian cattle and is the first disease to 
benefit from a DNA test (Hauge, 1989). Normal bovine 
cDNA for the enzyme (argininosuccinate synthetase) was 
isolated with a rat probe and sequenced by Dennis et al. 
(1989). 
(iii) Marple syrup urine disease (MSUD) in bovine results 
from a deficiency of the branched chain -ketoacid dehy-
drogenase, a mitochondrial multisubunit complex of enzy-
mes and the E1 component catalyses the oxidative de-
carboxylation (Hauge, 1989). MSUD has been identified 
both in humans and in cattle and is relatively common in 
the Polled Hereford breed of cattle in Australia. Studies 
on MSUD have also been reported by Hu et al. (1988); 
Zhang et al. (1990); Healy and Dennis (1994).   
(iv) Hyperkalemic periodic paralysis (HYPP) in Quarter 
Horses, a genetic disease observed among quarter 
horses (Hauge, 1989). The disease causes attacks of 
paralysis, inducible by ingestion of potassium. In humans, 
hyperkalemic periodic paralysis is caused by a single 
base substitution within the skeletal muscle sodium chan-
nel gene (Hauge, 1992). Studies on HYPP have also 
been reported by Rudolph et al. (1992a and b); Orita et 
al. (1989) and Neibergs et al. (1993).   
Others examples of the use of genetics for the 
diagnosis of disease mutations are Leukocyte adhesion 
deficiency in Cattle and malignant hyperthermia in pigs. 
 
 
Genetics and diagnosis of disease susceptibility 
 
The relationship between diseases and alleles of genes 
in the major histocompatibility complex (MHC) is also 
known for domestic animals (Hauge, 1989). This has 
been reported for Marek’s disease in chickens, which is 
caused by a herpes virus (Hanson et al., 1967; Hepkema 
et al., 1993); resistance to bovine leukosis, which is 
caused by BLV retrovirus, Lewin (1994) and Mejdell et al. 
(1994), reported an influence of the bovine MHC on 
resistance to mastitis. Andersson et al. (1986), Juul-
Madsen et al. (1993) and Park et al. (1993) have also re-
ported the association between diseases and alleles of 
genes in the major histocompatibility complex. More infor-
mative studies are now being conducted based on 
sequencing of the MHC polymorphic exons (Hauge, 1989)  




and such data have been presented for cattle (Andersson 
et al., 1991), sheep (Fabb et al., 1993), chickens (Moon 
Sung et al., 1993), horses (Szalai et al., 1993) and pigs 
(Vage et al., 1994).      
One major challenge in livestock improvement and pro-
ductivity is the question of sustainability especially when 
positive changes, which have, genetic basis have been 
accidentally achieved through mere phenotypic analysis. 
Only the detection and full exploitation of such genetic 
contents can sustain such changes and put disease inci-
dence, a significant component of productivity, on a per-
manent check.     
 
 
Genetics and drug formulations for animal health 
  
Drug development strategies have been influenced a lot 
by the potential targets offered by genome projects. Also, 
advances in genomics (Peltonen and McKusick, 2001; 
Janssens and Duijn, 2008), proteomics (Chung and 
Jordan, 2008) and understanding of the molecular 
mechanisms of diseases (Zhan, 2007) enable the search 
for new targets and facilitate the study of existing targets 
for finding clues to new target identification (Sakharkar et 
al., 2007; Sakharkar et al., 2007). These advances also 
help in probing the molecular mechanisms of drug 
actions, adverse drug reactions and the pharmacogenetic 
implications of variations in gene sequences and the 
profiles of gene expression and post-transcriptional pro-
cessing (Cotsarelis and Millar, 2001, Nicholls, 2003; Roth 
et al., 2004; Morphy and Rankovic, 2005; Roden et al., 
2006). 
As knowledge about the biology of diseases like cancer 
is ever increasing, the chances of developing better ways 
to prevent and cure such diseases have been improving 
rapidly by the use of genetic engineering. Individuals at 
high risk of developing genetic diseases could be 
monitored carefully through out their lives for early signs 
of the diseases, thus assuring early diagnosis and 
maximizing chances for successful therapeutic inter-
vention. Molecular biology has helped to advance the 
management of cancers in animals with the discovery 
and knowledge of P-glycoprotein. Considerable evidence 
has accumulated indicating that the multidrug transporter 
or P-glycoprotein plays a role in the development of 
simultaneous resistance to multiple cytotoxic drugs in 
cancer cells (Ambudkar et al., 1999). In recent years, 
various approaches such as mutational analysis and 
biochemical and pharmacological characterization had 
yielded significant information about the relationship of 
structure and function of P-glycoprotein. However, there 
is still considerable controversy about the mechanism of 
action of this afflux pump and its normal physiological 
role (Ambudkar et al., 1999). The final resolutions of the 
controversies surrounding P-glycoprotein and the ability 
to suppress its action could be a major breakthrough in 
the scientific world and a source of great relief to animal 





gene cloning and molecular biology approaches to the 
structure, function and regulation of cytochrome P450 
gene super family has enabled considerable progress in 
the characterization of cytochrome P450. A better under-
standing of the molecular mechanisms by which anti-
microbial resistance emerges and spreads should enable 
us in the future to design intervention strategies to reduce 
its progression (Chen et al., 2008). Aminov et al. (2001) 
reported the molecular ecology of tetracycline resistance: 
Development and validation of primers for detection of 
tetracycline resistance genes encoding ribosomal protec-
tion proteins. In their study, based on phylogenetic analy-
sis, a set of polymerase chain reaction (PCR) primers for 
detection, retrieval and sequence analysis of corres-
ponding gene fragments from a variety of bacterial and 
environmental sources were developed and characteri-
zed. A pair of degenerate primers targeted at all tetra-
cycline resistance genes were used to detect the circu-
lation of these genes in the rumen of cows, in swine feed 
and faeces and in swine faecal streptococci. The report 
by Aminov et al. (2001) was the first demonstration of the 
applicability of molecular ecology techniques to estimate 
the gene pool and the flux of antibiotic resistance genes 
in production. They reported that development of geno-
typing pools for detection and tracking of antibiotic resis-
tance genes in a variety of commensal and pathogenic 
bacteria, as well as in the environment, is essential for 
understanding the ecology of antibiotic resistance. Since 
their introduction in the 1950s, tetracyclines have been 
widely used in human and veterinary medicine, as growth 
promoters in animal industry and for prophylaxis in plant 
agriculture and aquaculture. At present, resistance to 
tetracyclines has spread to almost all bacteria genera 
and this situation is perhaps the consequence of previous 
overuse (Aminov et al., 2001). Their findings demand that 
there be further research targeted at development of 
genotyping tools for tracking the movement of antibiotic 
resistance genes in the environment. 
The goal of drug discovery is to create a single 
chemical substance (drug) that interacts specifically with 
a single molecular target to reinstate healthy state bio-
chemistry (Sakharkar and Sakharkar, 2008). However, it 
is observed that some of the most specific drugs are 
directed towards a target that is not central to the patho-
physiology of the disease and simply produce improve-
ments in a limited number of symptoms (Zheng et al., 
2006; Yildirim et al., 2007). Also, many drugs designed to 
interact with a single target have unexpected effects on 
‘‘off target’’ biochemical mechanisms (Greef and 
McBurney, 2005). Drug target networks are of general 
importance for the understanding of drug action 
(Sakharkar and Sakharkar, 2008).     
 
 
Genetics and plant toxicity in animals 
 
Fu et al. (2002) reported the genotoxic pyrrolizidine 





and tumorigenicity. In their report, they noted that plants 
that contain pyrolizidine alkaloids are widely distributed in 
nature and that although pyrrolizidine alkaloids have 
been shown to be genotoxic and tumorigenic in 
experimental animals, their mechanisms of actions have 
not been fully understood. They conducted mechanistic 
studies which suggested that pyrrolizidine alkaloids in-
duce tumours via a genotoxic mechanism mediated by 6, 
7-dihydro-7-hydroxy-1-hydroxymethyl 5H-pyrrolizine 
(DHP)-derived DNA adduct formation. They reported that 
this mechanism may be general to most carcinogenic 
pyrrolizidine alkaloids. Livestock are poisoned by grazing 
on plants containing pyrrolizidine alkaloids, causing 
livestock loss due to liver and pulmonary lesions (Smith, 
1981; Woo et al., 1988; Roeder, 1995; Stegelmeier et al., 
1991; Roeder, 2000). It is now well recognized that a 
large variety of animal species are susceptible to 
pyrrolizidine alkaloid toxicity (Mattocks, 1968; 1986; 
IARC, 1976). Pyrrolizidine alkaloids also contaminate 
sources of human food such as milk, wheat, honey, 
herbal medicines and herbal teas and this may potentially 
cause human health problems worldwide (Hirono et al., 
1976; Huxtable, 1980; Winship, 1991; Betz et al., 1994 
and Prakash et al., 1999). 
 
 
Genetics and ageing in mammals 
      
Molecular biology has also brought more light into the 
principle and causes of ageing in mammals. Since mole-
cular structure and function underlie all other levels of 
biological organization and since there are strong, 
precise research tools at this level, investigation of the 
molecular basis of ageing offers the prospect for both 
understanding and control of ageing (Brash et al., 1979).      
 
 
Diagnosis and treatment of genetic diseases   
 
Recombinant DNA technology has immensely contri-
buted to the diagnosis of genetic diseases in fetuses and 
is also used in the treatment of some genetic disorders in 
animals. The basic approach to diagnosis of disease in 
foetus is to obtain foetal cells by amniocentesis (that is, a 
sample of amniotic fluid taken by inserting a needle into 
the amniotic cavity) and then test for biochemical defects. 
However, genetic defects may not be recognizable in the 
amniotic fluid cells obtained by amniocentesis through 
routine biochemical methods only (Daini, 2000). In the 
case of lethal recessive mutations, gene cloning provides 
the potential for direct diagnosis. After a normal gene has 
been cloned, the nucleotide sequence and restriction 
endonuclease map has been determined, test can then 
be devised to detect the mutations responsible for that 
particular defects. Alternatively, the normal gene can be 
used as a probe to isolate or locate the corresponding 
gene from the DNA of the foetal cells (Daini, 2000). 




The restriction fragment length polymorphism (RFLP) is 
now being used as a tool in clinical diagnosis of human 
and animal diseases. This involves prenatal diagnosis 
using amniotic fluid, chorionic villus, northern and 
southern blotting, electrophoresis and hybridization. In 
developed countries, the use of RFLP in the diagnosis of 
diseases reduced the stress of gene disorders since a 
series of test will diagnose the abnormality and if it 
cannot be treated, then termination of such species may 
be necessary before birth (Correttee et al., 1998; Mosleni 
et al., 1998). Diagnosis and management of haemoglo-
binopathies is now possible through the use of RFLP 
analysis, indirect and direct analysis, using gene probe, 
gene expressions and other recombinant DNA techni-
ques (Embury, 1995; Morti et al., 1997). In cases where 
the clinical phenotype is the result of more than the 
genetic factor interacting with environmental factor, 
recombinant DNA technology may be used to identify 
those individuals in the population most at risk (Singuret 
and Andreux, 1997). Genetic engineering techniques are 
the most sensitive and reliable human DNA fingerprinting 
for use in forensic analysis (Daini, 2000). These techni-
ques could be maximized for the diagnosis and manage-
ment of animal diseases (Soetan, 2009). The use of 
recombinant DNA techniques in conjunction with conven-
tional genetic methods have led to a rapid increase in 
knowledge of the genetic map. Many animal genes have 
been mapped to chromosomes. A detailed genetic map is 
of great value in the diagnosis of genetic diseases and in 
the development of potential cures by gene therapy.   
 
 
APPLICATIONS OF GENE PROBES 
 
1. Restriction fragment length polymorphisms (RFLP). 
This exploits the fact that there is considerable pheno-
typically neutral sequence variation between individuals 
created by single base changes in the DNA sequence or 
by variation in the length of certain stretches of DNA due 
to insertion/deletion events (Daini, 2000). RFLP makes 
use of restriction endonucleases to determine if two or 
more DNA segments are similar. The segments being 
compared are cleaved or cut into discrete fragments with 
a restriction enzyme and separated according to size on 
an agarose gel. The gel is stained with ethidium bromide, 
visualized under ultraviolet (UV) light to reveal the 
fragments as bands on the gel, which can be 
photographed by instant polaroid camera. The resulting 
fragments, represented as bands on the photograph can 
be used to directly compare the different DNA segments. 
RFLP can be combined with Southern blotting and 
nucleic acid probes (Kwaga and Kabir, 1999). RFLP is 
also used to demonstrate the genetic basis of disease 
susceptibility due to the presence of unique polymor-
phism or sequences (Neibergs et al., 1994) or to deter-
mine whether a disease is caused by mutation. Changes 
in the virulence  of  certain  infectious  agents  have  been  




demonstrated to be due to the acquisition of genetic 
elements (DNA or RNA) that code for the traits. Extra-
chromosomal DNA (plasmids) that are known to be 
responsible for toxin production, antibiotic resistance and 
host adaptability have been shown in bacteria by the use 
of RFLP and other techniques (Farrar, 1983; Finlay, 
1992).     
RFLP is used predictively in antenatal diagnosis by 
determining which RFLP pattern a fetus at risk has 
inherited (Daini, 2000). This approach has been used in 
the clinical diagnosis of many monogenic disorders in 
animals.    
2. Gene probe is used for the direct analysis of gene 
mutations using gene-specific probes. The understanding 
of the molecular pathology of animal diseases is most 
detailed for some genetic diseases which show consi-
derable diversity in the molecular mechanisms of their 
aetiology for example haemoglobinopathies. 
3. Gene Mapping: Genetic maps are essential for diag-
nostic and therapeutic purposes and for understanding of 
gene expression and regulation. Gene mapping can be 
used for identifying a gene of interest known to be near 
another gene for which a clone is available (Daini, 2000). 
4. Indirect analysis using DNA probes: Recombinant DNA 
probes may also be used when the biochemical defect 
underlying a monogenic disorder is unknown. This again 
exploits linkage of a disease with RFLPs, but in this case 
the RFLPs are characterized by random cloned seg-
ments of DNA. The RFLPs may be localized several 
million base pairs away from the defective locus. RFLPs 
may be used as markers for mapping animal diseases. 
The RFLPs is used in the localization of genetic diseases 
where neither the biochemical defect nor the chromo-
some localization, has been particularly successful in the 
diagnosis of such diseases. 
5. Gene probes are used for the diagnosis of disease 
states or the presence of infectious micro-organisms in 
body fluids. The earlier methods used for the detection of 
micro-organisms are relatively slow and involve culture 
and this can take several days. In contrast, DNA probe 
technique can be done within minutes or hours and also 
need little expertise. The major biological tool used is 
monoclonal antibody, an innovation that has brought 
major advances on biology and medical sciences in the 
area of disease diagnosis. 
Gene probe is also used in the detection of sexually 
transmitted diseases and have advantages over the pre-
sent methods used which are inadequate and expensive. 
Gene probe is also used to detect canine distemper virus 
in canine species and salmonella strains that affects dairy 
products. Also probes for the Escherichia coli strain that 
causes scours, a form of pig diarrhoea that results in high 
pig mortality have been produced (Daini, 2000). 
6. Gene probes are also used in tissue typing.  It involves 
cloning of the series encoding the histocompatibility 
antigens (HLA) which are the proteins that define 





the immune system distinguishes between self and non-
self (foreign antigens). The HLA system is used in tissue 
typing for organ transplants, blood transfusions etc. 
Instead of using antibodies to detect proteins, it is now 
possible to use DNA probes to detect the genes that 
code for them.          
  
   
MARKER ASSISTED SELECTION (MAS) 
 
This is the process of the selection for a particular trait 
using genetic markers. MAS can accelerate the rate of 
genetic progress by increasing accuracy of selection and 
by reducing the generation interval. The advantages of 
MAS are that it is greatest for traits with low heritability. It 
facilitates increased rate of genetic gain by allowing 
measurement in young stock thereby reducing generation 
interval. MAS could also enhance future prospects for 
breeding for such traits as tolerance or resistance to 
environmental stresses, including diseases. Identification 
of carriers of genes for resistance and introduction of 
such genes into a particular animal could be used for 
resistance against diseases.  An example is the gene 
responsible for trypanotolerance in cattle. A genetic 
marker for a trait is a DNA segment which is associated 
with and hence segregates in a predictable pattern as the 
trait. Markers are also employed to determine the genetic 
relatedness in animals (Grunder et al., 1994; Medjugorac 
et al., 1994) using RFLP and other DNA fingerprinting 
methods, for purposes of trade, litigation or phylogenetic 
studies. DNA fingerprinting could also be used to accu-
rately trace offsprings to parents or genetic source.    
Results from studies involving allozyme analysis have 
also become useful in assisting selection as markers for 
making genetic improvement by reducing cost of drugs in 
management of livestock. Protein electrophoresis which 
separate alleles on fractionating gels such as polya-
crylamide, cellulose acetate or even starch gel have been 
used to study association between helminth resistance 
and  hemoglobin genetic fractions. Increase in selection 
pressure on the ‘a’ allele of the erythrocyte protein has 
been recommended for sheep because of the positive 
association between the allele and susceptibility to the 
infestation. Other gene products such as carbonic anhy-
drase, transferrin, albumin and glucose-6-phosphate 
dehydrogenase are being investigated so that other 






It is clear from the review that comprehensive solutions to 
a wide range of biological problems of humans and 
animals require adequate and in-depth knowledge of the 
structure of the gene and the regulatory sequences 





genetic bases. Mutations could affect the production of a 
given gene product in many different ways (Hauge, 
1989). Studies of haemoglobin synthesis in humans are 
examples of these possibilities. Replacement of a single 
base with another base as revealed in the study of micro 
satellites can produce the effect that an amino acid is 
replaced by another amino acid and one hundred and 
eighty-nine of such structural variants are known for the 
human ß-globin chain (Little, 1981). Genetics have been 
successfully used in the diagnosis of human diseases 
and gene therapy has been successfully utilized to pre-
vent or manage such diseases. There is an urgent need 
to maximize the critical role that genetics play in the 
diagnosis of diseases and this should be extended also 
to the area of veterinary sciences, especially in view of 
the recent outbreaks of animal diseases globally having 
adverse effects on human health for example avian 
influenza, swine influenza etc.  
Application of genetics to the diagnosis of animal disea-
ses can put veterinary scientists, public health experts, 
the policy makers and other stake holders a step ahead 
for the prevention and or quick management of infectious 
animal diseases which have economic and health conse-
quences. Therefore, collaborative researches between 
veterinary scientists and experts in the field of genetics 
are imperative and critical to the achievement of sus-
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